Navigation Links
Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
Date:1/21/2008

SWEDESBORO, N.J., Jan. 21 /PRNewswire/ -- Wedgewood Pharmacy has announced that it will continue to provide Avastin(R) (Bevacizumab) to retinal specialists and ophthalmologists who request it for their patients. The announcement responds to Avastin's manufacturer, Genentech's, decision (http://www.lucentis.com/lucentis/pdf/announcement.pdf) to stop supplying Avastin directly to compounding pharmacies as of January 1.

Avastin is commonly administered by retinal specialists and ophthalmologists to treat age-related wet macular-degeneration, a leading cause of blindness in the elderly. Although regulators haven't authorized Avastin's use against eye disease, it is chemically similar to Genentech's new product, Lucentis(R), which is about 50 times as costly as Avastin. On prescriptive authority of physicians, compounding pharmacies prepare, under sterile laboratory conditions, a once-monthly dose of the drug for use in the eye that costs about $40.

At Wedgewood, technicians trained in aseptic technique prepare Avastin 25mg/ml in individual syringes in a Class-1000 clean room under a Class-100 laminar-flow hood to assure sterility and quality.

"Many retinal specialists consider the Avastin treatment option as an indispensable part of their practices," said George Malmberg, RPH, FACA, FACVP the pharmacist president and CEO of Wedgewood Pharmacy. "We will continue to meet the critical and ongoing need for Avastin in ophthalmologic practice. Unlike other firms, we do not require that our customers make a long-term contractual agreement to purchase this vital medicine from us."

Avastin is an FDA-approved drug that is used in the treatment of metastatic colorectal cancer. Based on the pioneering work of Dr. Philip Rosenfeld, a professor of Ophthalmology at the world-renowned Bascom Palmer Eye Institute at the University of Miami, Miller School of Medicine, Avastin also has been used off-label by retinal specialists and ophthalmologists to treat thousands of patients with age-related macular degeneration (AMD), a disease that causes blindness.

About Wedgewood Pharmacy

A compounding pharmacy creates customized medications for individual patients in response to a licensed practitioner's prescription. Wedgewood Pharmacy is one of the largest compounding pharmacies in the United States, serving more than 20,000 prescribers of compounded medications. It is located in Swedesboro NJ and licensed throughout the United States.

Background: About Compounding Pharmacy

Because every patient is different and has different needs, customized, compounded medications are a vital part of quality medical care. The basis of the profession of pharmacy has always been the "triad," the patient- prescriber-pharmacist relationship. Through this relationship, patient needs are determined by a prescriber, who chooses a treatment regimen that may include a compounded medication. Prescribers often prescribe compounded medications for reasons that include (but are not limited to) the following situations:

-- When needed medications are discontinued by or generally unavailable

from pharmaceutical companies, often because the medications are no

longer profitable to manufacture;

-- When the patient is allergic to certain preservatives, dyes or binders

in available off-the shelf medications;

-- When treatment requires tailored dosage strengths for patients with

unique needs (for example, an infant);

-- When a pharmacist can combine several medications the patient is taking

to increase compliance;

-- When the patient cannot ingest the medication in its commercially

available form and a pharmacist can prepare the medication in cream,

liquid or other form that the patient can easily take; and

-- When medications require flavor additives to make them more palatable

for some patients.

For additional information, visit the International Academy of Compounding Pharmacists' Web site at http://www.iacprx.org and http://www.compoundingfacts.org.

Contact:

Marcy Kelly

Vice President, Marketing

mkelly@wedgewoodpharmacy.com

856.832.1303

David Kirk, APR, Fellow PRSA

davidkirk@thePRguy.com

610.422.0048


'/>"/>
SOURCE Wedgewood Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
4. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
5. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
6. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
7. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
8. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... 2016  Dovetail Genomics™ LLC today announced that it ... a planned metagenomic genome assembly service. Richard Green ... assembly method in a talk on Friday, February 12 ... conference in Orlando, Fla. ... is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology:
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):